- Home
- WPP vs HALO Comparison
WPP vs HALO Comparison
Compare WPP & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WPP
- HALO
- Stock Information
- Founded
- WPP 1985
- HALO 1998
- Country
- WPP United Kingdom
- HALO United States
- Employees
- WPP N/A
- HALO N/A
- Industry
- WPP Advertising
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WPP Consumer Discretionary
- HALO Health Care
- Exchange
- WPP Nasdaq
- HALO Nasdaq
- Market Cap
- WPP 8.4B
- HALO 7.4B
- IPO Year
- WPP N/A
- HALO N/A
- Fundamental
- Price
- WPP $40.10
- HALO $54.54
- Analyst Decision
- WPP Hold
- HALO Buy
- Analyst Count
- WPP 1
- HALO 9
- Target Price
- WPP N/A
- HALO $63.56
- AVG Volume (30 Days)
- WPP 311.7K
- HALO 3.3M
- Earning Date
- WPP 02-27-2025
- HALO 05-06-2025
- Dividend Yield
- WPP 2.99%
- HALO N/A
- EPS Growth
- WPP 389.11
- HALO 55.40
- EPS
- WPP 0.62
- HALO 3.76
- Revenue
- WPP $18,454,623,978.00
- HALO $1,084,306,000.00
- Revenue This Year
- WPP N/A
- HALO $25.77
- Revenue Next Year
- WPP $1.46
- HALO $18.01
- P/E Ratio
- WPP $12.63
- HALO $14.51
- Revenue Growth
- WPP N/A
- HALO 25.64
- 52 Week Low
- WPP $31.52
- HALO $42.01
- 52 Week High
- WPP $57.37
- HALO $70.51
- Technical
- Relative Strength Index (RSI)
- WPP 57.84
- HALO 44.48
- Support Level
- WPP $39.45
- HALO $52.43
- Resistance Level
- WPP $40.95
- HALO $54.26
- Average True Range (ATR)
- WPP 0.50
- HALO 3.42
- MACD
- WPP 0.05
- HALO -0.49
- Stochastic Oscillator
- WPP 65.86
- HALO 30.60
About WPP WPP plc
Headquartered in the United Kingdom, WPP is one of the world's largest ad holding companies based on annual revenue. Its services, which include traditional and digital advertising, public relations, and consulting, are provided worldwide, with over 70% of its revenue coming from more developed regions such as North America, the UK, and Western Europe.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.